LQDA
Liquidia Corporation · Healthcare · Medical - Pharmaceuticals
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 99 | +23 | 36.66M | $2.92B | +26 | −3 |
| Q1 2026 | 79 | -1 | 26.51M | $999.68M | +6 | −8 |
| Q4 2025 | 81 | 0 | 26.44M | $911.45M | +1 | — |
| Q3 2025 | 17 | +1 | 21.94M | $498.92M | +1 | — |
| Q2 2025 | 13 | -2 | 14.83M | $184.82M | — | −2 |
| Q1 2025 | 12 | 0 | 5.71M | $84.24M | — | — |
| Q4 2024 | 12 | +4 | 4.81M | $56.51M | +4 | — |
| Q3 2024 | 7 | -2 | 2.07M | $20.68M | +1 | −3 |
| Q2 2024 | 9 | — | 2.26M | $27.08M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 1.31M | — | $15.74M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Two Sigma Investments ✦ | 346.12K | — | $4.15M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Millennium Management ✦ | 180.06K | — | $2.16M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 159.99K | — | $1.92M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 156.70K | — | $1.88M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Marshall Wace ✦ | 45.45K | — | $545,448 | 0.0% | n/c | 1 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 23.76K | — | $285,084 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | T. Rowe Price ✦ | 18.36K | — | $221,000 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 13.95K | — | $167,376 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 242 holders, 61.34M shares, $2.26B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 235.48K sh · $6.39M
Director · 8.47K sh · $560,243
Director · 9.02K sh · $619,210
Officer · 274 sh · $18,566
Officer · 31.80K sh · $2.20M
Officer · 41.83K sh · $2.89M
Director · 18.39K sh · $1.33M
Director · 36.79K sh · $2.76M
Officer · 50.00K sh · $3.70M
Officer · 29.53K sh · $2.27M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology